{"t":"DOCUMENT","c":"","l":0,"ch":[{"t":"CONTAINER","c":"html","l":1,"ch":[{"t":"CONTAINER","c":"head","l":2,"ch":[{"t":"CONTAINER","c":"title","l":3},{"t":"CONTAINER","c":"meta","l":3}]},{"t":"CONTAINER","c":"body","l":2,"ch":[{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"ix:header","l":4,"ch":[{"t":"CONTAINER","c":"ix:hidden","l":5,"ch":[{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"0001757499","l":7}]},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"false","l":7}]}]},{"t":"CONTAINER","c":"ix:references","l":5,"ch":[{"t":"CONTAINER","c":"link:schemaref","l":6}]},{"t":"CONTAINER","c":"ix:resources","l":5,"ch":[{"t":"CONTAINER","c":"xbrli:context","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:entity","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:identifier","l":8,"ch":[{"t":"SECTION_TITLE","c":"0001757499","l":9}]}]},{"t":"CONTAINER","c":"xbrli:period","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:startdate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2023-03-16","l":9}]},{"t":"CONTAINER","c":"xbrli:enddate","l":8,"ch":[{"t":"SECTION_TITLE","c":"2023-03-16","l":9}]}]}]},{"t":"CONTAINER","c":"xbrli:unit","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":7,"ch":[{"t":"SECTION_TITLE","c":"iso4217:USD","l":8}]}]},{"t":"CONTAINER","c":"xbrli:unit","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":7,"ch":[{"t":"SECTION_TITLE","c":"xbrli:shares","l":8}]}]},{"t":"CONTAINER","c":"xbrli:unit","l":6,"ch":[{"t":"CONTAINER","c":"xbrli:divide","l":7,"ch":[{"t":"CONTAINER","c":"xbrli:unitnumerator","l":8,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":9,"ch":[{"t":"SECTION_TITLE","c":"iso4217:USD","l":10}]}]},{"t":"CONTAINER","c":"xbrli:unitdenominator","l":8,"ch":[{"t":"CONTAINER","c":"xbrli:measure","l":9,"ch":[{"t":"SECTION_TITLE","c":"xbrli:shares","l":10}]}]}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"UNITED\nSTATES","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"UNITED\nSTATES","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"UNITED\nSTATES","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"SECURITIES\nAND EXCHANGE COMMISSION","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"SECURITIES\nAND EXCHANGE COMMISSION","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"SECURITIES\nAND EXCHANGE COMMISSION","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Washington,\nD.C. 20549","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Washington,\nD.C. 20549","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Washington,\nD.C. 20549","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"8-K","l":8}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"CURRENT\nREPORT","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"CURRENT\nREPORT","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"CURRENT\nREPORT","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"March 16, 2023","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"March 16, 2023","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"March 16, 2023","l":8}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":6},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"SHUTTLE\nPHARMACEUTICALS HOLDINGS, INC.","l":8}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"(Exact\nname of registrant as specified in its charter)","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"(Exact\nname of registrant as specified in its charter)","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Delaware","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"001-41488","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"82-5089826","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"(State\n    or other jurisdiction ofIncorporation)","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"(CommissionFile Number.)","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"(IRS\n    EmployerIdentification\n    No.)","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"One\nResearch Court","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"One\nResearch Court","l":7}]}]},{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"Suite 450","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"Suite 450","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Rockville","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"Rockville","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"Maryland","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"Maryland","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"20850","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"20850","l":8}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"(Address\nOf Principal Executive Offices) (Zip Code)","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"(Address\nOf Principal Executive Offices) (Zip Code)","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"240","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"240","l":8}]}]},{"t":"CONTAINER","c":"span","l":6,"ch":[{"t":"SECTION_TITLE","c":"430-4212","l":7},{"t":"CONTAINER","c":"ix:nonnumeric","l":7,"ch":[{"t":"SECTION_TITLE","c":"430-4212","l":8}]}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Registrant’s\ntelephone Number, including Area Code","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Registrant’s\ntelephone Number, including Area Code","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Written\n    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Soliciting\n    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Pre-commencement\n    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"☐","l":6},{"t":"TABLE_CELL","c":"Pre-commencement\n    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Securities\nregistered pursuant to Section 12(b) of the Act:","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Securities\nregistered pursuant to Section 12(b) of the Act:","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Title\n    of each class","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Trading\n    Symbol(s)","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Name\n    of each exchange on which registered","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Common\n    Stock $0.00001 per share","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"SHPH","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"TheNasdaqStock Market LLC","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"☒","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"☒","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"CONTAINER","c":"span","l":5,"ch":[{"t":"SECTION_TITLE","c":"☐","l":6},{"t":"CONTAINER","c":"ix:nonnumeric","l":6,"ch":[{"t":"SECTION_TITLE","c":"☐","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"CONTAINER","c":"div","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"","l":7}]}]}]}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item\n1.01 Entry Into A Material Definitive Agreement Definitive Agreement","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item\n1.01 Entry Into A Material Definitive Agreement Definitive Agreement","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item\n1.01 Entry Into A Material Definitive Agreement Definitive Agreement","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 16, 2023, Shuttle Pharmaceuticals Inc. (“Shuttle Pharma”), a Maryland corporation and the wholly-owned subsidiary of\nShuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into a research agreement (the “Research\nAgreement”) with Georgetown University (“Georgetown”) for testing small molecule radiation sensitizers and immune activation\ncandidates discovered and developed by Shuttle Pharma in cell-based and animal xenograft models. Under the Research Agreement, Georgetown\nwill provide researching and testing services to Shuttle Pharma for a total estimated cost of $128,400. The Research Agreement\nhas a term of one year from April 1, 2023 through March 31, 2024.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 16, 2023, Shuttle Pharmaceuticals Inc. (“Shuttle Pharma”), a Maryland corporation and the wholly-owned subsidiary of\nShuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into a research agreement (the “Research\nAgreement”) with Georgetown University (“Georgetown”) for testing small molecule radiation sensitizers and immune activation\ncandidates discovered and developed by Shuttle Pharma in cell-based and animal xenograft models. Under the Research Agreement, Georgetown\nwill provide researching and testing services to Shuttle Pharma for a total estimated cost of $128,400. The Research Agreement\nhas a term of one year from April 1, 2023 through March 31, 2024.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"In\nconjunction with the Research Agreement, Shuttle Pharma entered into a material transfer agreement (the “MTA”), dated March\n21, 2023, with Georgetown. Under the MTA, Shuttle Pharma agreed to transfer research quantities of candidate drug molecules to\nGeorgetown, which Materials will be used by Georgetown solely to carry out additional research for Shuttle Pharma and which Materials\nshall at all times remain the property of Shuttle Pharma.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"In\nconjunction with the Research Agreement, Shuttle Pharma entered into a material transfer agreement (the “MTA”), dated March\n21, 2023, with Georgetown. Under the MTA, Shuttle Pharma agreed to transfer research quantities of candidate drug molecules to\nGeorgetown, which Materials will be used by Georgetown solely to carry out additional research for Shuttle Pharma and which Materials\nshall at all times remain the property of Shuttle Pharma.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"The\nforegoing summaries of each of the Research Agreement and the MTA do not purport to be complete and is each qualified in its entirety\nby reference to the Research Agreement and MTA, which are attached as Exhibits 10.1 and 10.2 hereto and incorporated herein by reference.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"The\nforegoing summaries of each of the Research Agreement and the MTA do not purport to be complete and is each qualified in its entirety\nby reference to the Research Agreement and MTA, which are attached as Exhibits 10.1 and 10.2 hereto and incorporated herein by reference.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item\n4.01 Changes in Registrant’s Certifying Accountant.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item\n4.01 Changes in Registrant’s Certifying Accountant.","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item\n4.01 Changes in Registrant’s Certifying Accountant.","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 21, 2023, the Company’s audit committee selected FORVIS LLP (the “New Accountant”) to serve as the\nCompany’s independent registered public accounting firm for the review of its Quarterly Reports on Form 10-Q and Annual Report\non Form 10-K for the year ending December 31, 2023. As a result, the audit committee determined that BF Borgers CPA PC (the\n“Former Accountant”) would no longer serve as the Company’s independent registered public accounting firm,\neffective as of March 21, 2023.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 21, 2023, the Company’s audit committee selected FORVIS LLP (the “New Accountant”) to serve as the\nCompany’s independent registered public accounting firm for the review of its Quarterly Reports on Form 10-Q and Annual Report\non Form 10-K for the year ending December 31, 2023. As a result, the audit committee determined that BF Borgers CPA PC (the\n“Former Accountant”) would no longer serve as the Company’s independent registered public accounting firm,\neffective as of March 21, 2023.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"The\nFormer Accountant’s audit report on our financial statements for the years ended December 31, 2021 and 2022 contained no adverse\nopinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except that\nthe audit report on the financial statements of the Company for the year ended December 31, 2021 contained an uncertainty about the Company’s\nability to continue as a going concern (the “Going Concern Opinion”). The Former Auditor’s Going Concern Opinion was\nresolved following the Company’s completion of its approximately $11.4 million initial public offering in September 2022 and subsequent\n$4.0 million private placement in January 2023.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"The\nFormer Accountant’s audit report on our financial statements for the years ended December 31, 2021 and 2022 contained no adverse\nopinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles, except that\nthe audit report on the financial statements of the Company for the year ended December 31, 2021 contained an uncertainty about the Company’s\nability to continue as a going concern (the “Going Concern Opinion”). The Former Auditor’s Going Concern Opinion was\nresolved following the Company’s completion of its approximately $11.4 million initial public offering in September 2022 and subsequent\n$4.0 million private placement in January 2023.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"For\nthe years ended December 31, 2022 and 2021 and through the date of this Current Report on Form 8-K, the Company had no “disagreements”\n(as defined in Regulation S-K, Item 304(a)(1)(iv) and the related instructions) with the Former Accountant on any matter of accounting\nprinciples or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the\nsatisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for\nsuch periods.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"For\nthe years ended December 31, 2022 and 2021 and through the date of this Current Report on Form 8-K, the Company had no “disagreements”\n(as defined in Regulation S-K, Item 304(a)(1)(iv) and the related instructions) with the Former Accountant on any matter of accounting\nprinciples or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the\nsatisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for\nsuch periods.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"There\nwere no reportable events for the years ended December 31, 2022 or 2021 and through the date of this Current Report on Form 8-K, there\nwere no reportable events as defined in item 304(a)(1)(v) of Regulation S-K.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"There\nwere no reportable events for the years ended December 31, 2022 or 2021 and through the date of this Current Report on Form 8-K, there\nwere no reportable events as defined in item 304(a)(1)(v) of Regulation S-K.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Prior\nto retaining the New Accountant, the Company did not consult with the New Accountant regarding either: (i) the application of accounting\nprinciples to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company’s\nfinancial statements; or (ii) any matter that was the subject of a “disagreement” or a “reportable event” (as\nthose terms are defined in Item 304(a)(1)(iv) and (a)(1)(v) of Regulation S-K, respectively).","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Prior\nto retaining the New Accountant, the Company did not consult with the New Accountant regarding either: (i) the application of accounting\nprinciples to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company’s\nfinancial statements; or (ii) any matter that was the subject of a “disagreement” or a “reportable event” (as\nthose terms are defined in Item 304(a)(1)(iv) and (a)(1)(v) of Regulation S-K, respectively).","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 21 2023, the Company provided the Former Accountant with the disclosures contained in this Current Report on Form 8-K\ndisclosing the dismissal of the Former Accountant and requested in writing that the Former Accountant furnish the Company with a\nletter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. The Former\nAccountant’s response is filed as Exhibit 16.1 to this Current Report on Form 8-K.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 21 2023, the Company provided the Former Accountant with the disclosures contained in this Current Report on Form 8-K\ndisclosing the dismissal of the Former Accountant and requested in writing that the Former Accountant furnish the Company with a\nletter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. The Former\nAccountant’s response is filed as Exhibit 16.1 to this Current Report on Form 8-K.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item 7.01 Regulation FD Disclosure","l":4},{"t":"CONTAINER","c":"b","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item 7.01 Regulation FD Disclosure","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 22, 2023, the Company posted an updated investor presentation on its website at www.shuttlepharma.com. A copy of the updated investor\npresentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 22, 2023, the Company posted an updated investor presentation on its website at www.shuttlepharma.com. A copy of the updated investor\npresentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"","l":7}]}]}]}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"PARAGRAPH","c":"p","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item\n8.01 Other Events","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item\n8.01 Other Events","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item\n8.01 Other Events","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 22, 2023, the Company issued a press release announcing that Shuttle Pharma entered into the Research Agreement set forth\nin Item 1.01 above. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated\nby reference herein.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"On\nMarch 22, 2023, the Company issued a press release announcing that Shuttle Pharma entered into the Research Agreement set forth\nin Item 1.01 above. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated\nby reference herein.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"The information set forth\nin Item 7.01 and Item 8.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and\nshall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item\n10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933,\nas amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such\nfiling. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Item\n9.01 Financial Statements and Exhibits.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Item\n9.01 Financial Statements and Exhibits.","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"Item\n9.01 Financial Statements and Exhibits.","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"(d)","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Exhibits","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Exhibit\n    No.","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Description","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"10.1","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Research Agreement, dated March 16, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"10.2","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Material\n    Transfer Agreement, dated March 21, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"16.1","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Letter from BF Borgers CPA PC to\n    the Securities and Exchange Commission","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"99.1","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Press Release of Shuttle Pharmaceuticals Holdings, Inc. dated March 22, 2023","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"99.2","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Investor Deck, dated March 22, 2023","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"104","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"Cover\n    Page Interactive Data File (embedded within the Inline XBRL document)","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"2","l":7}]}]}]}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"SIGNATURES","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"SIGNATURES","l":5},{"t":"CONTAINER","c":"b","l":5,"ch":[{"t":"SECTION_TITLE","c":"SIGNATURES","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.","l":4},{"t":"CONTAINER","c":"span","l":4,"ch":[{"t":"SECTION_TITLE","c":"Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.","l":5}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"TABLE","c":"table","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Dated:\n    March 22, 2023","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"SHUTTLE\n    PHARMACEUTICALS HOLDINGS, INC.","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"By:","l":6},{"t":"TABLE_CELL","c":"/s/\n    Anatoly Dritschilo","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Name:","l":6},{"t":"TABLE_CELL","c":"Anatoly\n    Dritschilo","l":6},{"t":"TABLE_CELL","c":"","l":6}]},{"t":"TABLE_ROW","c":"tr","l":5,"ch":[{"t":"TABLE_CELL","c":"Title:","l":6},{"t":"TABLE_CELL","c":"Chief\n    Executive Officer","l":6},{"t":"TABLE_CELL","c":"","l":6}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"CONTAINER","c":"div","l":3,"ch":[{"t":"TABLE","c":"table","l":4,"ch":[{"t":"TABLE","c":"table","l":5,"ch":[{"t":"TABLE_ROW","c":"tr","l":6,"ch":[{"t":"TABLE_CELL","c":"3","l":7}]}]}]}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]},{"t":"PARAGRAPH","c":"p","l":3,"ch":[{"t":"CONTAINER","c":"span","l":4}]}]}]}]}